Aerie Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference
BEDMINSTER, N.J., RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 11:30a.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and business update.
The presentation will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company has commenced two Phase 3 registration trials in the United States, named "Rocket 1" and "Rocket 2," where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol, and has received a "no objection letter" from Health Canada to initiate a third Phase 3 safety trial, named "Rocket 3," in Canada. The Company also recently completed a Phase 2b clinical trial where RoclatanTM met the primary efficacy endpoint, demonstrating statistical superiority of Roclatan™ to each of its components.